Personalized Intervention Based on Early Detection of Atherosclerosis

Journal of the American College of Cardiology, Journal Year: 2024, Volume and Issue: 83(21), P. 2112 - 2127

Published: May 1, 2024

Language: Английский

---

Antioxidant and Anti-Inflammatory Effects of Bioactive Compounds in Atherosclerosis

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1379 - 1379

Published: Feb. 6, 2025

Atherosclerosis, a chronic inflammatory disease characterized by the accumulation of lipids and immune cells within arterial walls, remains leading cause cardiovascular morbidity mortality worldwide. Oxidative stress inflammation are central to its pathogenesis, driving endothelial dysfunction, foam cell formation, plaque instability. Emerging evidence highlights potential bioactive compounds with antioxidant anti-inflammatory properties mitigate these processes promote vascular health. This review explores mechanisms through which compounds-such as polyphenols, carotenoids, flavonoids, omega-3 fatty acids, coenzyme Q10, other natural compounds-modulate oxidative in atherosclerosis. It examines their effects on key molecular pathways, including inhibition reactive oxygen species (ROS) production, suppression nuclear factor-κB (NF-κB), modulation cytokines. By integrating current knowledge, this underscores therapeutic dietary supplemental complementary strategies for managing atherosclerosis, paving way future research clinical applications.

Language: Английский

---

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Journal of clinical lipidology, Journal Year: 2023, Volume and Issue: 17(4), P. 491 - 503

Published: June 3, 2023

Obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), non-high-density (non-HDL-C), particles, and apolipoproteins, when added to high-intensity statin in patients with dyslipidemia.To evaluate the safety lipid-altering efficacy of obicetrapib plus ezetimibe combination therapy as an adjunct therapy.This double-blind, randomized, phase 2 trial administered 10 mg (n = 40), 39), or placebo 40) for 12 weeks LDL-C >70 mg/dL triglycerides (TG) <400 mg/dL, on stable statin. Endpoints included concentrations lipids, proprotein convertase subtilisin kexin type 9 (PCSK9), safety, tolerability.Ninety-seven were primary analysis (mean age 62.6 years, 63.9% male, 84.5% white, average body mass index 30.9 kg/m2). decreased from baseline week by 63.4%, 43.5%, 6.35% combination, monotherapy, groups, respectively (p<0.0001 vs. placebo). levels <100, <70, <55 achieved 100%, 93.5%, 87.1%, respectively, taking combination. Both active treatments also significantly reduced non-HDL-C, apolipoprotein B, total small LDL particles. Obicetrapib was well tolerated no issues identified.The lowered atherogenic lipid parameters, safe top elevated LDL-C.

Language: Английский

---

Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association

Arteriosclerosis Thrombosis and Vascular Biology, Journal Year: 2023, Volume and Issue: 43(10)

Published: Sept. 14, 2023

The objective of this scientific statement is to evaluate contemporary evidence that either supports or refutes the conclusion aggressive low-density lipoprotein cholesterol lowering lipid exerts toxic effects on brain, leading cognitive impairment dementia hemorrhagic stroke. writing group used literature reviews, references published clinical and epidemiology studies, public health guidelines, authoritative statements, expert opinion summarize existing identify gaps in current knowledge. Although some retrospective, case control, prospective longitudinal studies suggest statins are associated with dementia, preponderance observational data from randomized trials do not support conclusion. risk a stroke statin therapy patients without history cerebrovascular disease nonsignificant, achieving very low levels does increase risk. Data reflecting lipid-lowering treatment among robust require additional focused study.

Language: Английский

---

Dioscin pretreatment ameliorates ferroptosis in cardiomyocytes after myocardial infarction via inhibiting endoplasmic reticulum stress

Molecular Medicine, Journal Year: 2025, Volume and Issue: 31(1)

Published: Jan. 29, 2025

Language: Английский

---

Nuts and Cardiovascular Disease Outcomes: A Review of the Evidence and Future Directions

Nutrients, Journal Year: 2023, Volume and Issue: 15(4), P. 911 - 911

Published: Feb. 11, 2023

Nuts are nutrient-rich foods that contain many bioactive compounds beneficial for cardiovascular health. Higher consumption of nuts has been associated with a reduced risk several diseases (CVD) in prospective cohort studies, including 19% and 25% lower CVD incidence mortality, respectively, 24% 27% coronary heart disease respectively. An 18% stroke 15% atrial fibrillation, total mortality have also observed. The role incidence, subtypes, peripheral arterial failure less consistent. This narrative review summarizes recommendations by clinical practice guidelines governmental organizations, epidemiological evidence outcomes, nut-containing dietary patterns, potential mechanisms reduction, future research directions, such as the use biomarkers to help better assess nut intake. Although there still some uncertainties around prevention which require further research, summarized this review, is substantial amount supports consuming will positive impact on primary secondary CVD.

Language: Английский

---

Eliminating atherosclerotic cardiovascular disease residual risk

European Heart Journal, Journal Year: 2023, Volume and Issue: 44(45), P. 4731 - 4733

Published: July 14, 2023

Language: Английский

---

A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review PART II—Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(5), P. 1508 - 1508

Published: March 5, 2024

Background: Aging is a key risk factor for atherosclerosis progression that associated with increased incidence of ischemic events in supplied organs, including stroke, coronary events, limb ischemia, or renal failure. Cardiovascular disease the leading cause death and major disability adults ≥ 75 years age. Atherosclerotic occlusive affects everyday activity, quality life, it reduced life expectancy. As most multicenter randomized trials exclude elderly very patients, particularly those severe comorbidities, physical cognitive dysfunctions, frailty, residence nursing home, there insufficient data on management older patients presenting atherosclerotic lesions outside territory. This results serious critical gaps knowledge lack guidance appropriate medical treatment. In addition, due to variety comorbidities elderly, average daily number pills taken by octogenarians exceeds nine. Polypharmacy frequently drug therapy problems related interactions, toxicity, falls injury, delirium, non-adherence. Therefore, we have attempted gather treatment extra-cardiac indicating where some evidence are evidence-based medicine. Public PubMed databases were searched review existing effectiveness lipid-lowering, antithrombotic, new glucose-lowering medications disease.

Language: Английский

---

Simulation model to assess the validity of the clinical portfolio diet score used in the PortfolioDiet.app for dietary self-tracking: a secondary analysis of a randomized controlled trial in hyperlipidemic adults

Frontiers in Nutrition, Journal Year: 2024, Volume and Issue: 11

Published: Aug. 7, 2024

The Portfolio Diet combines cholesterol-lowering plant foods for the management of cardiovascular disease risk. However, translation this dietary approach into clinical practice necessitates a user-friendly method patients to autonomously monitor their adherence.

Language: Английский

---

Role of Phytochemicals in Cardiovascular Disease Management: Insights into Mechanisms, Efficacy, and Clinical Application

Phytomedicine Plus, Journal Year: 2024, Volume and Issue: unknown, P. 100695 - 100695

Published: Nov. 1, 2024

Language: Английский

---